Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iradimed (IRMD) EPS (Weighted Average and Diluted) (2016 - 2026)

Iradimed has reported EPS (Weighted Average and Diluted) over the past 14 years, most recently at $0.45 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 21.62% to $0.45 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.83 through Mar 2026, up 18.06% year-over-year, with the annual reading at $1.75 for FY2025, 16.67% up from the prior year.
  • EPS (Weighted Average and Diluted) was $0.45 for Q1 2026 at Iradimed, down from $0.5 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.5 in Q4 2025 and troughed at $0.2 in Q1 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.37 (2025), against an average of $0.36.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 116.67% in 2022 against a maximum downside of 3.23% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.3 in 2022, then increased by 20.0% to $0.36 in 2023, then increased by 11.11% to $0.4 in 2024, then grew by 25.0% to $0.5 in 2025, then fell by 10.0% to $0.45 in 2026.
  • Per Business Quant, the three most recent readings for IRMD's EPS (Weighted Average and Diluted) are $0.45 (Q1 2026), $0.5 (Q4 2025), and $0.43 (Q3 2025).